Safe Implant Technology ApS
Private limited companyCVR 38969153FårevejleActive
Safe Implant Technology ApS is a private limited company, based in Fårevejle, active in research and experimental development on natural sciences and engineering, founded in 2017. Equity was negative at the end of 2025 (−DKK 946k). The company made a loss in both 2024 and 2025, most recently DKK 53,855.
Key figures · financial year 2025
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- The loss got smaller: from DKK 725k to DKK 53,855 (2024 → 2025).
Registrations, last 24 months
- 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2020–2025 · amounts in DKK thousandEquity and net profit
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | not stated | not stated | not stated | – |
| Gross profit | −3 | −7 | −6 | −195 | −58 | 756 | +1,403.7% |
| Operating profit (EBIT) | −3 | −7 | −6 | −195 | −725 | −54 | +92.5% |
| Profit before tax | −3 | −7 | −7 | −195 | −725 | −54 | +92.6% |
| Net profit | −3 | −7 | −7 | −195 | −725 | −54 | +92.6% |
| Total assets | 393 | 711 | 924 | 1,584 | 1,239 | 1,658 | +33.8% |
| Equity | 41 | 34 | 27 | −168 | −892 | −946 | −6% |
| Liabilities | 352 | 677 | 897 | 1,752 | 2,132 | 2,604 | +22.2% |
| Cash and cash equivalents | 0 | 9 | 0 | 584 | 83 | 453 | +445.8% |
| Average number of employees | 0 | 0 | 0 | 0 | 2 | 2 | 0% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresNegative equity
Equity was −DKK 946k at the end of 2025.
How is this calculated?
Equity in the latest annual report is below zero.
Loss for 6 years in a row
Net result has been negative in 2020–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
6 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 10/07/2026 | The company | PDF not statedXBRL |
| 2024 | 01/01/2024 – 31/12/2024 | 06/07/2025 | The company | PDF not statedXBRL |
| 2023 | 01/01/2023 – 31/12/2023 | 08/07/2024 | The company | PDF not statedXBRL |
| 2022 | 01/01/2022 – 31/12/2022 | 15/07/2023 | The company | PDF not statedXBRL |
| 2021 | 01/01/2021 – 31/12/2021 | 04/07/2022 | The company | PDF not statedXBRL |
| 2020 | 01/01/2020 – 31/12/2020 | 13/07/2021 | The company | PDF not statedXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 49,385of 69,742 Better than 29% | No. 67,060of 69,964 Better than 4% |
| Same industry and fewer than 20 employees329 companies in the comparison | No. 130of 323 Better than 60% | No. 251of 329 Better than 24% |
| Companies that are between 5 and 14 years old33,688 companies in the comparison | No. 25,451of 33,588 Better than 24% | No. 31,833of 33,687 Better than 6% |
| All companies of type ApS66,508 companies in the comparison | No. 47,534of 66,379 Better than 28% | No. 63,577of 66,505 Better than 4% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineering- Safe Implant Technology ApSDKK 756k
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Safe Implant Technology ApS−DKK 53,855
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
- Safe Implant Technology ApS−DKK 946k
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
- Safe Implant Technology ApS2
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- Devopharma ApS66.67%
- Berlock ApS15%
Management
5 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Henrik Nakskov | Director | 25/09/2017 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Lone Damgaard Horup | Board member | 12/10/2017 |
| Henrik Nakskov | Board member | 12/10/2017 |
| Gorm Danscher | Board member | 12/10/2017 |
| Søren Luplau-Pagh | Chair of the board | 12/10/2017 |
- Founders
- Berlock ApS, Devopharma ApS
Signing rule: Selskabet tegnes af selskabets direktør og et bestyrelsesmedlem
Address and production units
1 active production unitsHyldvej 1A
4540 Fårevejle
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Safe Implant Technology ApS | Hyldvej 1A, 4540 Fårevejle | 2 | 1022880345 |
Purpose
Selskabets formål er at udøve virksomhed med forskning og eksperimentel udvikling indenfor bioteknologi
The purpose is quoted from the register in Danish.
Changes year by year
16 registered events20261 changeaccounts 1
- AccountsAnnual report for 2025 published
20252 changesaccounts 1 · industry 1
- AccountsAnnual report for 2024 published
- IndustryIndustry changed to Research and experimental development on natural sciences and engineering (721000)
20242 changesaccounts 1 · address 1
- AccountsAnnual report for 2023 published
- AddressMoved to Hyldvej 1A, 4540 Fårevejle
20231 changeaccounts 1
- AccountsAnnual report for 2022 published
20221 changeaccounts 1
- AccountsAnnual report for 2021 published
20211 changeaccounts 1
- AccountsAnnual report for 2020 published
20178 changesmanagement 5 · founded 1 · ownership 2
- ManagementLone Damgaard Horup appointed board member
- ManagementHenrik Nakskov appointed board member
- ManagementGorm Danscher appointed board member
- ManagementSøren Luplau-Pagh appointed chair of the board
- FoundedRegistered as Safe Implant Technology ApS
- ManagementHenrik Nakskov appointed director
- OwnershipDevopharma ApS registered as owner (66.67%)
- OwnershipBERLOCK ApS registered as owner (15%)
Related companies
Same people in management
- Capgemini Danmark A/Svia Søren Luplau-Pagh
- Venzo A/Svia Søren Luplau-Pagh
- Capgemini Services Danmark ApSvia Søren Luplau-Pagh
- P-secure ApSvia Søren Luplau-Pagh
- Redpill Linpro Connect A/Svia Søren Luplau-Pagh
- Aeon Group A/Svia Søren Luplau-Pagh
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.